Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis

Inclusion Criteria: * Subjects must have a body mass index (BMI) at screening within the range of 18 - 46 kg/m2. BMI = Body weight (kg) / \[Height (m)\]2 * Biopsy proven pulmonary sarcoidosis diagnosed \> 1 year prior to screening * Scadding stage II, III or IV as determined by the most recent chest x-ray obtained within 12 months prior to screening or at screening (confirmed by the Investigator) * HRCT extent of fibrosis \<20% (confirmed by the central imaging reader) at screening * Treatment with 5-15 mg/day prednisone (or prednisone oral equivalents) for ≥ 6 months prior to screening. * Co-medication with methotrexate or azathioprine for ≥ 6 months prior to screening (Note: hydroxychloroquine is allowed as background therapy but not required) * Able to perform reliable, reproducible pulmonary function test maneuvers per American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines Exclusion Criteria: * Diagnosis of significant pulmonary hypertension (WHO group 5) requiring pharmacological treatment * Active cardiac sarcoidosis requiring treatment. Inactive cardiac sarcoidosis or stable cardiac sarcoidosis not requiring treatment are permissible. * A known diagnosis of neurosarcoidosis * Forced vital capacity (FVC) \<50% of predicted at screening (central read) * Modified British Medical Research Council (mMRC) dyspnea scale ≥ 3 at screening * Concomitant treatment with leflunomide, cyclophosphamide, mycophenolate, infliximab, etanercept, adalimumab, golimu…